Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|January 27, 2015
The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trialKimberley E Steele, Joseph Canner, Gregory Prokopowicz, et al.Journal for Immunotherapy of Cancer|July 7, 2021
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevanceTricia Cottrell, Jiajia Zhang, Boyang Zhang, et al.Journal of the American College of Radiology : JACR|May 7, 2021
ACR Appropriateness Criteria® Imaging of Mediastinal Masses, Jeanne B Ackman, Jonathan H Chung, et al.Journal of the American College of Radiology : JACR|November 27, 2022
ACR Appropriateness Criteria® Suspected Pulmonary Embolism: 2022 Update, Jacobo Kirsch, Carol C Wu, et al.Cancer Discovery|December 30, 2016
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Kellie N Smith, Patrick M Forde, et al.Journal for Immunotherapy of Cancer|September 15, 2020
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancerJoshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, et al.Nature Cancer|September 28, 2020
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancerValsamo Anagnostou, Noushin Niknafs, Kristen Marrone, et al.The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.Cancer Research|December 14, 2018
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung CancerValsamo Anagnostou, Patrick M Forde, James R White, et al.Journal for Immunotherapy of Cancer|March 8, 2019
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.Pageof 4